Replies to post #14805 on Hemispherx BioPharma (HEB)

[JohnnyD3]

You'll probably need to consider this December update as the update to that open letter.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119341791

The NIH clinical study referred to in the post will be announced tomorrow at CDC Public Health Grand Rounds.

http://www.cdc.gov/cdcgrandrounds/archives/2016/february2016.htm

I expect an ampligen trial will be next on the list. They needed to get their own intramural study underway as a first move. I don't think there will ever be an update to the meeting requested in the letter - they'll just go ahead and do a clinical trial.

BTW, Charles Lapp is on the June 5 letter.

[JohnnyD3]

Lutfiyah, more dot connecting... which I obviously like to do.

The CDC began a multi-site clinical assessment of CFS in 2012. There are 7 clinical sites. These are most of the leading U.S. experts in CFS. Patients enrolling in the new NIH Post-Infectious ME/CFS study will come from these clinical centers.

http://www.cdc.gov/cfs/programs/clinical-assessment/

There are 7 centers, with these expert clinicians: Peterson, Klimas, Lapp, Bateman, Podell, Kogelnik, Natelson

6 out of 7 signed the Open Letter to the FDA requesting ampligen be approved.